RecruitingNot applicableNCT05858424
Impact of a Multidisciplinary End-of-treatment Day Hospital on the Quality of Life of Adolescents and Young Adults With Cancer
Studying Lymphoma
Last synced from ClinicalTrials.gov
ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing dataKey facts
- Sponsor
- Centre Leon Berard
- Principal Investigator
- Amandine BERTRAND, MDInstitut d'Hématologie et d'Oncologie Pédiatrique
- Intervention
- Multidisciplinary day hospitalization(other)
- Enrollment
- 214 target
- Eligibility
- 15-25 years · All sexes
- Timeline
- 2022 – 2026
Study locations (1)
- Centre Leon Berard, Lyon, France
Primary source
Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.
Open NCT05858424 on ClinicalTrials.govOther trials for Lymphoma
Additional recruiting or active studies for the same condition.
- RECRUITINGPHASE1NCT07511426U96-CAR-T-Cells For R/R B-ALLThe First Affiliated Hospital of Soochow University
- RECRUITINGPHASE2NCT07316010Phase 2 Trial of Lisocabtagene Maraleucel for Minimal Residual Disease in Patients With Large B-cell LymphomaM.D. Anderson Cancer Center
- RECRUITINGPHASE2NCT07372352Zeprumetostat, Azacitidine Combined With Lipo-MIT in R/R PTCLThe First Affiliated Hospital of Soochow University
- RECRUITINGPHASE1, PHASE2NCT07575919Targeted CD22/CD19 CAR-T Therapy for Consolidation in Standard-Risk B-ALLLiping Dou
- ACTIVE NOT RECRUITINGPHASE1NCT07198087A Study to Investigate the Pharmacokinetics of Tirabrutinib in Participants With Mild, Moderate, and Severe Hepatic Impairment Compared to Healthy ParticipantsOno Pharmaceutical Co. Ltd
- RECRUITINGPHASE1NCT07140016A Study of Gilteritinib in Adults With Advanced ALK-positive Non-small Cell Lung Cancer (NSCLC)Astellas Pharma Global Development, Inc.
- RECRUITINGNANCT07191431A Clinical Study on the Efficacy and Safety of Methotrexate (MTX) or Thiotepa (for MTX Intolerance) or Temozolomide (TMZ) Combined With Orelabrutinib and Selinexor in Relapsed/Refractory Primary or Secondary Central Nervous System Lymphoma（SELINA）Ruijin Hospital
- RECRUITINGPHASE1, PHASE2NCT07018752A Platform Trial Evaluating New Drugs or Combination in R/R Peripheral T-cell LymphomasThe Lymphoma Academic Research Organisation